key: cord-0852015-hmspjncj authors: Chowdhary, Anuradha; Sharma, Amit title: The lurking scourge of multidrug resistant Candida auris in times of COVID-19 pandemic date: 2020-06-12 journal: J Glob Antimicrob Resist DOI: 10.1016/j.jgar.2020.06.003 sha: d1d02838d75d01416a28624494fa9ea036b822e9 doc_id: 852015 cord_uid: hmspjncj nan patients is their tendency to develop acute respiratory distress syndrome that requires ICU admission, mechanical ventilation and/or extracorporeal membrane oxygenation [1] . Reports from several countries suggest flooding of hospital ICUs by COVID-19 patients that require respiratory support ranging from high-flow nasal cannula to invasive ventilation. This haunting facet of COVID-19 pandemic has severely challenged even the most advanced hospital settings. Yet one potential confounder, not in the immediate attention of most healthcare professionals, is the secondary transmission of multidrug resistant organisms like the fungus Candida auris in COVID-19 ICUs [2] . Before the arrival of SARS-CoV-2, C. auris was considered a major global health threat due to high rates of drug resistance and ease of transmission in hospital settings. Indeed, multidrug resistant C. auris has been reported from over 40 countries across six continents since its first description a decade ago. Given the nosocomial transmission of SARS-CoV-2 by those infected, many hospital environments may serve as venues for C. auris transmission as it is a known environmental colonizer of ICUs. C. auris patients shed viable yeast cells from their skin continuously and thereby contaminate hospital environments. C. auris outbreaks occur in critically ill hospitalized patients and can result in mortalities rates ranging from 30% to 72% [3] . Both C. auris and SARS-CoV-2 has been found on hospital surfaces including on bedrails, IV poles, beds, air conditioner ducts, windows and hospital floors [4, 5] . Therefore, the standard COVID-19 critical care of mechanical ventilation and protracted ventilator-assisted management makes these patients potentially susceptible to colonization and infections by C. auris. Multidrug-resistant C. auris isolates with resistance to all three main classes of antifungals have been described in India and Kenya [9, 10] . In a study in India it was established that C. auris accounted for 5% of candidemia cases in a paediatric hospital, and 30% of cases in a tertiary general hospital from intensive care unit [11] . Therefore, the importance of rapidly identifying this yeast in developing countries with high burden of C auris such as Africa and India is warranted to prevent an outbreak in COVID 19 patients that could be difficult to We declare no competing interests. No funding was received for the correspondence Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Candida auris: a global fungal public health threat Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. tertiary care hospital with a Candida auris outbreak Increase in methicillin-resistant Staphylococcus aureus acquisition rate and change in pathogen pattern associated with an outbreak of severe acute respiratory syndrome Control of Candida auris in healthcare institutions Candida auris-an impending threat: A case report from home Tracing the evolutionary history and global expansion of Candida auris using population genomic analyses A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: Role of the ERG11 and FKS1 genes in azole and echinocandin resistance New clonal strain of Candida auris